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A
mAbstract
AGuIX nanoparticles are formed of a polysiloxane network surrounded by
gadolinium chelates. They present several characteristics. They are easy to produce,
they present very small hydrodynamic diameters (<5 nm) and they are
biodegradable through hydrolysis of siloxane bonds. Such degradation was
evaluated in diluted conditions at physiological pH by dynamic light scattering and
relaxometry. AGuIX nanoparticles are also known as positive contrast agents and
efficient radiosensitizers. The aim of this paper is to compare their efficiency for
magnetic resonance imaging and radiosensitization to those of the commercial
gadolinium based molecular agent: DOTAREM®. An experiment with healthy animals
was conducted and the MRI pictures we obtained show a better contrast with the
AguIX compared to the DOTAREM® for the same amount of injected gadolinium in
the animal. The better contrast obtained after injection of Aguix than DOTAREM® is
due to a higher longitudinal relaxivity and a residential time in the blood circulation
that is two times higher. A fast and large increase in the contrast is also observed by
MRI after an intravenous injection of the AGuIX in 9 L gliosarcoma bearing rats, and
a plateau is reached seven minutes after the injection.
We established a radiotherapy protocol consisting of an irradiation by microbeam
radiation therapy 20 minutes after the injection of a specific quantity of gadolinium.
After microbeam radiation therapy, no notable difference in median survival time
was observed in the presence or absence of gadolinium chelates (38 and 44 days
respectively). In comparison, the median survival time is increased to 102.5 days with
AGuIX particles showing their interest in this nanomedicine protocol. This remarkable
radiosensitizing effect could be explained by the persistent tumor uptake of the
particles, inducing a significant nanoscale dose deposition under irradiation.
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As emphasized by J. N. Long et al. in a recent review [1], molecular gadolinium
chelates and in particular those involving 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-
accetic acid (DOTA) have been extensively developed and used in biomedical imaging
for the last 25 years. First used for magnetic resonance imaging (MRI), DOTA(Gd3+)
(commercially known as DOTAREM®) offers the advantage of a better thermodynamic
association constant as well as lower dissociation kinetic rates in comparison to acyclic2014 Le Duc et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
ttribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
edium, provided the original work is properly credited.
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agent and avoid nephrogenic systemic fibrosis (NFS) [3] that might be induced by the
in vivo demetallation of gadolinium. DOTA and DOTA derivatives can also be used for
the chelation of radioactive isotopes (e.g. 111In or 64Cu) to perform single photon emis-
sion computed tomography (SPECT) [4] or positron emission tomography (PET) [5].
They can be coupled to various types of targeting ligands (e.g. antibodies [6], peptides
[7], aptamers [8]) to render the imaging more sensitive and efficient. In line with the
recent development of fused instruments to perform multimodal imaging (PET/MRI
(Magnetic Resonance Imaging), SPECT/CT or PET/CT (computed tomography), Fluor-
escence/MRI) [9], DOTA based Gd3+ complexes can be associated with other imaging
agents, such as radionuclide chelators or organic luminescent probes [10-12].
Another strategy to enhance the imaging contrast and to permit multimodal imaging
as well as theranostic applications has been proposed recently. It consists in coupling
the chelating species to the surface of nanoparticles [13,14], or to incorporate them into
nanostructures [15]. As MRI suffers from low sensitivity [16], coupling gadolinium
chelates to nanostructures is an advantage for MRI because it enhances the longitudinal
relaxivity both per object (by grafting multiple chelates on one object) and per
gadolinium (by increasing the rotational correlation time) [17]. Another advantage of
using nanoparticles is that they do not present any extravasation from normal vessels
and are accumulated passively in tumors via the enhanced permeability and retention
(EPR) effect [18]. Finally, the use of efficient MRI contrast agents provides a better
delineation of the tumor and consequently a better image guidance for further
radiotherapy protocol. The clinical interest for image guided radiation therapy (IGRT)
is for example emphasized by the partnership between Elekta (radiotherapy systems
manufacturers) and Philips (medical imaging specialists) [19]. In this context,
gadolinium is playing an important role because of its intrinsically properties for MRI
and because of its relatively high atomic number value (Z = 64). This is important since
many molecules [20] containing bromine (Z = 35), iodide (Z = 53), gadolinium or
platinum (Z = 78) or nanoparticles [21] made with gold (Z = 79) have shown great
potential in radiosensitization. Since the pioneering work of Hainfeld et al. [21] a large
number of experimental reports using particles with different photon source energies
as well as different cell lines confirms the interest in nanoparticles to enhance the
clinical irradiation efficiency [22,23]. For the moment, the most studied gadolinium-based
radiosensitizer is Motexafin Gadolinium (MGd). It contains a porphyrin like macrocycle
that chelates gadolinium. MGd can be detected by MRI and is currently in the phase III
of clinical development as a radiosensitizer for irradiation of brain tumors [24-26]. As
theoretical work and experiments suggest that heavy elements in nanoparticles improve
radiosensitization [22], our team has developed a family of ultrasmall gadolinium based
nanoparticle for MRI and radiosensitization called AGuIX (Activation Guided by
Irradiation by X-rays). Two main types of nanoparticles were proposed that present very
similar in vivo behaviors. The first nanoparticles consist of a polysiloxane core coated with
DTPA (Diethylene Triamine Pentaacetic Acid) [27] and have demonstrated their potential
for IGRT. To completely prevent any release of gadolinium, a new generation of nanopar-
ticles incorporating DOTA was proposed [28,29]. For their synthesis, a DOTA derivative:
DOTAGA [30,31] (GA =Glutaric Acid) was used for the grafting on the nanoparticle.
The additional arm of this macrocycle is used to form an amide bond leaves eight
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coordination mode leads to a similar association constant towards gadolinium for
the DOTAGA grafted on the nanoparticle compared to molecular DOTA towards
gadolinium (log β = 24.78 and 25.58 respectively) [29]. Interestingly, the two types
of nanoparticles have very similar physico-chemical properties, radiosensitizing
properties and in vivo biodistribution profiles. The aim of this paper is to demonstrate the
interest of these nanoparticles supporting gadolinium chelates for the treatment of glioma
by IGRT compared to using small gadolinium chelates.Methods
Chemicals
Gadolinium chloride hexahydrate ([GdCl3, 6H2O], 99.999%), sodium hydroxide (NaOH,
99.99%), tetraethyl orthosilicate (Si(OC2H5)4, TEOS, 98%), aminopropyl-triethoxysilane
(H2N(CH2)3-Si(OC2H5)3, APTES, 99%), triethylamine (TEA, 99.5%), 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES, 99.5%), sodium hydroxide (NaOH, 99.99%),
sodium chloride (NaCl, 99.8%), calcium chloride (CaCl2, 99%), the bovine serum
albumin and dimethyl sulfoxide (DMSO, 99.5%) were purchased from Aldrich Chemicals
(France). Diethylene glycol (DEG, 99%) was purchased from SDS Carlo Erba (France).
Acetone (reagent grade) was purchased from Sodipro (France) and was used in the same
conditions as received. 1,4,7,10-tetraazacyclododecane-1-glutaric anhydride-4,7,10-triace-
tic acid (DOTAGA) was furnished by CheMatech (Dijon, France). Gadolinium oxide cores
were furnished by Nano-H S.A.S (Saint-Quentin Fallavier, France). Only milli-Q water
was used for the preparation of aqueous solutions of nanoparticles.Characterization
DLS (Dynamic Light Scattering) size measurement
Direct measurements of the size distribution (in DEG) or after dilution (at 10 mM in
[Gd3+] for water) of the nanoparticles were performed via Zetasizer NanoS DLS (laser
He-Ne 633 nm) from Malvern Instrument.ζ-potential measurements
Direct determination of the ζ-potential of the hybrid nanoparticles were performed via
a Zetasizer NanoS from Malvern Instruments. Prior to the experiment, the nanoparticles
were diluted in an aqueous solution containing 0.005 M in NaCl and adjusted to the
desired pH.Inductively coupled plasma-atomic emission spectrometry (ICP-AES) analysis
Determination of the gadolinium content in a sample was performed by ICP-AES
analysis (with a Varian 710-ES spectrometer). Before measuring gadolinium concentra-
tion, samples of colloidal solution were dissolved in concentrated nitric acid for
24 hours. The samples were then diluted with water, until the nitric acid concentration
in water reached 5%. Chemical analyses were also performed on the as-prepared
samples at the Service Central d’Analyses du CNRS (Solaize, France) by ICP-AES, and
enabled determining the C, N, Si contents with a precision of 0.5%.
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Relaxation time measurements were performed using a Bruker Minispec MQ60 NMR
analyser, operating at 1.4 T magnetic field.
High performance liquid chromatography (HPLC)
Gradient HPLC analysis was done by using Shimadzu Prominence series UFLC
system with a CBM-20A controller bus module, a LC-20 AD liquid chromatograph,
a CTO-20A column oven and a SPD-20A UV-visible detector. UV-visible absorption was
measured at 295 nm. 20 μL of sample were loaded in the solvent injection ratio: 95%
solvent A – 5% solvent B (A =Milli-Q water/TFA 99.9:0.1 v/v; B = CH3CN/Milli Q water/
TFA 90:9.9:0.1 v/v/v) onto a Jupiter C4 column (150 × 4.60 mm, 5 μm, 300 Å, Phenom-
enex) at a flow rate of 1 mL/min over 5 min. In a second step, samples were eluted by a
gradient developed from 5 to 90% of solvent B in solvent A over 15 min. The concen-
tration of solvent B was maintained over 5 min. Then, the concentration of solvent B was
decreased to 5% over a period of 5 min to re-equilibrate the system, followed by additional
5 min at this final concentration. Before each sample measurement, a baseline
was performed following the same conditions by loading Milli-Q water into the
injection loop.
Particles synthesis
Preparation of gadolinium oxide cores [32]
A solution was prepared by dissolving 167.3 g of [GdCl3, 6 H2O] in 3 L of DEG at
room temperature. The solution is then stirred for 3 hours at 140°C. Afterwards,
44.5 mL of sodium hydroxide solution (10 M) is added to the solution. This final solu-
tion is stirred for 5 hours at 180°C before cooling and stirring for 12 hours at ambient
temperature. The gadolinium oxide cores displayed hydrodynamic diameters of 1.7 ±
0.5 nm.
Encapsulation of gadolinium oxide cores by polysiloxane
The polysiloxane shell is ensured by sol–gel process by addition of silane precursors.
First, a solution containing 1.6 L of DEG, 51.42 mL of TEOS and 80.61 mL of APTES
is slowly added (during 96 hours) to the precedent solution under stirring at 40°C. One
hour after the end of the addition of the silane precursors, a second solution of 190 mL
of DEG, 43.1 mL of water and 6.94 mL of TEA is added under stirring at 40°C during
96 hours. At the end of the second addition, the solution is stirred for 72 hours at 40°C
and finally for 12 hours at ambient temperature. The gadolinium oxide cores coated by
the polysiloxane displayed hydrodynamic diameter of 2.6 ± 1.0 nm.
Covalent grafting of DOTAGA on the nanoparticles
163.7 g of DOTAGA anhydride are then added to the core-shell nanoparticles in DEG.
The resulting solution is stirred for 72 hours at room temperature.
Purification
17.5 L of acetone are added to the solution to precipitate the nanoparticles that are
filtered under vacuum before dispersion in water. The solution is stirred for one hour
at pH 2 before remaining acetone is removed by evaporation. The nanoparticles are
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at pH 5 for 12 hours before another tangential filtration through 5 kDa membrane after
addition of sodium hydroxide solution to reach pH 7.4. Afterward, the solution is
filtered twice through a 1.2 μm and then 0.2 μm syringe filters to remove the
largest impurities. Finally, the nanoparticles are freeze-dried and can be stored for
months without alterations. After dispersion in water, the AGuIX nanoparticles
display hydrodynamic diameter of 2.2 ± 1 nm. Elementary analysis found (weight
percent) C, 26.84; N, 7.79; Gd, 13.83; Si, 10.79. An average mass of 8.7 ± 1 kDa is
obtained by mass spectrometry. The longitudinal relaxivity (r1) is 11.5 mM
−1.s−1 at
1.4 T. The nanoparticles display an isoelectric point at pH 7.5 ± 0.5. About 50 g of
nanoparticles are obtained at the end of the synthesis. HPLC chromatogram, with
UV absorption detection at 295 nm, shows a retention time of 10 min for the
nanoparticles.
Imaging and MRT procedure
All operative procedures related to experiments on glioma bearing rats strictly con-
formed to the French government regulations with licenses 380825 and B3818510002
and were approved by the internal evaluation committee for animal welfare and rights
of the ESRF. All operative procedures related to MR on healthy mice strictly conformed
to the Guidelines of the French Government with licenses 380324 and A3818510002
for MRI on healthy mice. All experiments were performed under anesthesia with the
following parameters: 5% isoflurane for induction and intraperitoneal injection of
xylazine/ketamine (64.5/5.4 mg.kg−1) for maintenance.
Brain tumor inoculation
The 9 L gliosarcoma (9LGS) cells were implanted in the brain of male fisher F344 rats
(Charles River, France) [33]. Anesthetized animals were placed on stereotactic frame,
and 104 9LGS cells were suspended in 1 μL culture medium with antibiotics before to
be injected through a burr hole in the right caudate nucleus (3.5 mm lateral to the
bregma, 6 mm below the skull surface).
Preparation of injectable solution
After tangential filtration, a concentrated colloid (AGuIX in water, [Gd3+] = 100 mM)
was diluted by aqueous solution containing NaCl and hepes in order to obtain an
intravenous use solution ([Gd3+] = 40 mM, [NaCl] = 145 mM, [hepes] = 10 mM). The
pH was adjusted to 7.4. Before use, this solution was filtered onto syringe filter
with nylon membrane (pore diameter 0.22 μm). The chelate used was DOTAREM®
(laboratories Guerbet, Aulnay sous Bois France, 0,5 mM/mL) as available in MRI units.
Drug injection
The aqueous AGuIX ([Gd3+] = 40 mM, [NaCl] = 145 mM, [hepes] = 10 mM) colloid
was manually injected in the saphena vein at 1.4 mL volume using a 2 mL syringe and
a 26 G needle. The gadolinium chelates were injected via the saphena vein according 2
protocols. First, a series of rats received an injection of a colloidal solution at the
concentration of 1 M in Gd , i.e. twice the concentration routinely used in clinical
conditions (0.5 mM). The volume injected was of 56 μL which corresponds to a
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rats received a 1.4 mL DOTAREM® injection diluted in physiological serum until
40 mM (to establish a direct comparison with the nanoparticles, the quantity of Gd
injected being the same than previously).MR imaging
The MR imaging took place at Grenoble Institute of Neuroscience (GIN) using a 7
Tesla Imaging system (Biospec, Bruker, Erlangen Germany) equipped with a 400 mM/T
gradient. The images were made 14 days after implantation, and the rats were injected
in the saphena vein with 1.4 ml of a Gd based particles solution at 40 mM in gadolin-
ium. Images were acquired at fixed times after injection using a T2 weighted Turbo
RARE SE sequence (TR = 4,000 ms, TE = 33 ms, FOV = 3 cm, Resolution = 0,12 mm,
ST = 1 mm) and a T1 weighted FLASH sequence (TR = 840 ms, TE = 10,804 ms, FOV
= 3 cm, Resolution + 0,12 mm, ST = 1 mm).Radiation source and microbeam radiation therapy (MRT) set-up
Irradiations were performed at the ID17 Biomedical Beamline of the European
Synchrotron Radiation Facility (ESRF, France) using X-rays emitted tangentially
from electron bunches circulating in a storage ring. The wiggler produces a wide
spectrum of photons which extends, after filtration, from 50 over 350 keV (median
energy: 90 keV). The mean dose rate was then 62 Gy.mA−1.s−1 allowing very fast
irradiation. The quasilaminar beam was micro-fractionated into an array of 41 rect-
angular and quasi-parallel 50 microns width microbeams, separated by 200 microns
centre to centre. The setup was performed by using the ESRF Multislit Collimator,
positioned 33 m from the photon source, and 80 cm upstream from the rat holder.
Ten days after tumor inoculation, the animals were positioned prone on a Kappa-
type goniometer (Huber, Germany) in front of the X-rays source, on a homemade
Plexiglas frame, and the alignment into the beam was performed using live cam-
eras. The contention of the rats was performed by a teeth bar, while the animals
were under anaesthesia. They were received a lateral irradiation, from their ana-
tomical right to left side, followed by an antero-posterior irradiation (cross fired
configuration). The beam was shaped into a field of irradiation of 10 mm horizon-
tal, and the animals were scanned vertically over 10 mm through the beam after
opening of the shutter. Although the total procedure lasted about 2 min, for each
rat, the irradiation time is around 2 s. Animal immobility during exposure was
checked on three control video screens located in the control hutch. The micro-
beam dose at the tumor (i.e. 7 mm of depth from lateral side) was 400Gy, the
valley dose was 18.6 Gy as computed by Monte Carlo simulations. The spatial con-
figuration of irradiation was checked by radiochromic films (Gafchromic, HD-810)
exposed in front of rats.
Survival analysis
The survivals of animals were represented on Kaplan −Meier curves and compared
using the log-rank test; the Median Survival time (MeST) postimplantation was
calculated (Prism, GraphPad Software, San-Diego, USA).
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Synthesis
A protocol for the synthesis of AGuIX has been previously published [28,29]. A scale-
up synthesis has been developed in order to produce larger quantities of nanoparticles
for in vivo applications and further potential clinical applications. The first step is the
formation of a gadolinium oxide core by a slow addition of NaOH solution on gadolinium
trichloride previously dissolved in diethylene glycol at high temperature. The gadolinium
oxide cores are then coated by a polysiloxane shell by addition of suitable silane
precursors. DOTAGA anhydride is then added to the nanoparticles; the chelate is
grafted by a peptide bond on the surface of the polysiloxane matrix. The dispersion
of these nanoparticles in water leads to the dissolution of the gadolinium oxide
core which is induced by the chelation of the gadolinium by the ligands. As a
result, ultrasmall nanoparticles are obtained, displaying hydrodynamic diameter of
2.1 ± 1 nm and a mass of 8.7 ± 1 kDa [29]. They are composed of a polysiloxane
core surrounded by about ten gadolinium chelates displaying hydrodynamic
diameter of 2.1 ± 1 nm and a mass of 8.7 ± 1 kDa.
Characterization of the biodegradation
The nanoparticles present biodegradable properties in diluted or basic media. A
cleavage of the oxygen-silicon bonds is observed in these conditions, leading to smaller
nanoparticles that possess the same characteristics than the initial ones: they are also
made of polysiloxane and surrounded by gadolinium chelates [34]. In order to
characterize the dissolution process, the freeze-dried nanoparticles have been dispersed
at 50 mM (in Gd3+) at physiological pH in a solution containing 0.1 M of sodium
chloride and 1.5 mM of calcium chloride and stirred at this concentration for one hour
to permit homogeneous dispersion of the nanoparticles. They are diluted ([Gd3+] =
2.5 mM) in a solution containing 0.1 M of sodium chloride and 1.5 mM of calcium
chloride. The hydrodynamic diameter obtained by DLS has been plotted versus time
for a temperature of 37°C (See Figure 1). The curve has been fitted by a mono-
exponential decay curve and lead to a half-life of about 19.6 minutes. Moreover, the
degradation can be followed by relaxometry thanks to the longitudinal relaxivity (r1),
which is higher for greater nanoparticles mass due to an increase in the rotational
correlation time [17]. Temporal evolution of r1 per gadolinium has been plotted afterFigure 1 Study of the degradation of the nanoparticle in diluted media after dilution at 2.5 mM. a)
Black circles correspond to temporal evolution of the hydrodynamic diameter. b) Temporal evolution of the
longitudinal relaxivity. In the two cases, red lines correspond to monoexponential decay fit.
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than human serum (See Figure 1). After fitting hydrodynamic diameter and relaxivity
by a mono-exponential decay curve, a similar half-life of 17.9 minutes is observed,
indicating a non-negligible degradation in diluted solutions close to in vivo conditions.
The degradation life-time is close to the order of magnitude of the residence time,
which may explain the observed efficiency of the renal elimination.
MRI study
On healthy animals
The AGuIX nanoparticles have been intravenously injected (80 μL at 40 mM in Gd) on
8-weeks-old c57B1/6 J mice and have been followed by MRI at 7 T (r1 = 6 mmol
−1.s−1)
[28]. A rapid highlight of the kidney and then of the bladder is observed (about 5 and
25 minutes after the intravenous injection of the nanoparticles respectively). A similar
dose of DOTAREM® (80 μL at 40 mM in Gd) was injected in the mice and the
residence time of the nanoparticles in the blood was found to be about two times
higher for AGuIX than for DOTAREM® (13.2 minutes for AGuIX versus 6.8 min for
DOTAREM®). This higher residence time leads to a larger imaging window for the
nanoparticles in comparison to the chelates. Angiography images show a clear highlight
of the blood brain vessels with a better contrast for the nanoparticles due to the higher
relaxivity and the longer residence time in the blood circulation. Interestingly, the
nanoparticles are eliminated from the kidney according to a multi-exponential law. The
entire nanoparticles are eliminated more slowly than the partially degraded that pass
directly from the kidneys to the bladder. The full nanoparticles are first taken up by
renal cells of the cortex region before complete elimination.
On tumor bearing animals
Previous studies on brain glioma bearing rats have shown that gadolinium chelates
injected intravenously can provide clear highlights of the tumors [35]. Interestingly, the
contrast to noise ratio (CNR) is maximal 1–3 minutes after the injection and decreases
very rapidly. For example, U. I. Attenberger et al. have injected GADOVIST®,
DOTAREM® and MAGNEVIST® in glioma bearing rats [35]. For DOTAREM®, they ob-
tained tumor Signal to Noise Ratio (SNR) on a 1.5 T apparatus of 30.9 ± 4.4, 54.1 ± 3.8,
51.6 ± 5.9, 45.7 ± 2.5, 44.1 ± 2.2 and 41.4 ± 1.5 (before injection and 1 min, 3 min,
5 min, 7 min and 9 min post-injection respectively). The rapid decrease in the gadolin-
ium concentration in the tumor, which is in the same order of magnitude than the
elimination time of the chelates from the blood, is problematic to determine the most
suited moment for irradiation (i.e. higher content of gadolinium in the tissue combined
to the lower one in the surrounding healthy tissues).
AGuIX nanoparticles accumulate passively in tumors thanks to the enhanced perme-
ability and retention effect (EPR effect) [36], firstly described by Maeda et al. [18]. In
the specific case of brain, the nanoparticles and the chelates cannot cross the blood
brain barrier unless it is compromised by a pathology like a tumor. The DTPA based
AGuIX nanoparticles have previously shown passive accumulation in 9LGS glioma-
bearing rats [27]. This specific gliosarcoma model has been chosen due to its character-
istics close to human gliomas (high proliferative capability, high vascularization and
high infiltrative pattern) [33]. DOTAGA based AGuIX nanoparticles have been injected
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signal have been observed in both rats and are completely similar. It is then shown in
Figures 2 and 3 for only one of the rats.
A small increase in the signal was observed in the healthy tissue of the rats, followed
by a rapid decrease a few minutes after the injection. Conversely, a significant enhance-
ment of the MRI signal was noticed in the tumor. It reached a plateau about 7 minutes
after the intravenous injection of the nanoparticles (See Figure 3). After 1 day, a weak
MRI signal can be still visualized in the tumor due to the presence of the nanoparticles
(See Figure 4). The persistence of the signal is due to the very slow leakage of the nano-
particles from the tumor. The capacity of the nanoparticles to remain in the tumor
even hours after their injection is a real asset to determine an adapted radiotherapy
protocol. Contrary to the gadolinium chelates that present a rapid elimination from the
tumor, the nanoparticles are rapidly cleared from healthy tissues while conserving a
high and relatively constant concentration in the tumor.
In vivo radiosensitization survival curves
A comparison was performed between the efficiencies of molecular complexes, such as
gadolinium chelates (DOTAREM®) and of chelates incorporated at the surface of
ultrasmall nanoparticles (AGuIX), under the same irradiation conditions, i.e. 20 min,
after intravenous injection. The short delay of 20 min has been chosen to maintain a
relatively high gadolinium concentration in the tumor during irradiation when using
the chelates. In a first experiment, two experimental conditions were tested for the
chelates. The same quantity of gadolinium (56 μmol) was injected in all the expe-
riments. For the chelates, two different gadolinium concentrations were used: (i)
[Gd3+] = 1 M (injected volume of 56 μL), close from the concentrations used for
DOTAREM® in clinic protocol and (ii) [Gd3+] = 40 mM (injected volume of 1.4 mL), the
concentration used with nanoparticles. These two different concentrations were used in
order to determine if the initial concentration of the solution has an influence upon the
survival curves (See Figure 5). Regardless of the concentration, almost no difference is
observed between the survival curves when the irradiation is performed in presence or inFigure 2 T1-weigthed images of the brain of a 9 L bearing rat: a) 7 and b) 11 minutes after
intravenous injection of AGuIX nanoparticles.
Figure 3 Temporal evolution of the MRI signal in tumor (black squares) and in an equivalent
surface in normal tissue in the left hemisphere (red circles).
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irradiation only) (See Table 1). These median survival times are higher than for non-
treated animals (MeST of 19 days). This corresponds to an increase in lifespan (ILS) of
131%, 126% and 68% for irradiation alone or in presence of gadolinium chelates injected
20 minutes before at Gd concentrations of 40 mM and 1 M respectively.Figure 4 T1-weigthed images of the brain of a 9LGS bearing rat 1 day after intravenous injection of
AGuIX nanoparticles.
Figure 5 Survival curves of 9LGS bearing rats without treatment (black curve, n = 9 rats), only
treated by MRT (red curve, n = 15 rats), and treated by MRT 20 min after an injection of 1 M (56 μL)
of DOTAREM® (blue curve, n = 8 rats), a unique injection of 40 mM (1.4 mL) of DOTAREM® (green
curve, n = 8 rats) or AGuIX (pink curve, n = 8 rats), 10 days after tumor implantation. The MRT
irradiation was done in cross-fired mode, using 50 μm wide micro-beams, with a spacing of 200 μm
between the beams. The skin entrance dose was set at 400 Gy for the peak and 20 Gy for the valley.
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of the AGuIX nanoparticles (1.4 mL and [Gd3+] = 40 mM) with the same amount of
gadolinium than after injection of DOTAREM® leads to an important increase of the
MeST to 102.5 days. It corresponds to an impressive ILS of 439%. A significant
difference is found between particles and chelates associated to MRT (p < 0.0035 and p
< 0.0158 for the 1 M injection and the 40 mM injection using the log rank test).
Conclusion
To conclude, the treatment of glioma bearing rats with MRT after injection of AGuIX
nanoparticles leads to an important increase in the survival of aggressive glioma
bearing rats. On the contrary, no evidence of such increase has been observed with the
combination of MRT and gadolinium chelates. The accumulation of particles in brainTable 1 MeST of the 9LGS bearing rats without irradiation, after MRT irradiation (i) only,
(ii) in presence of DOTAREM® and (iii) in presence of particles (with the same quantity of
gadolinium)
Median survival time (Days) Number of rats
Without irradiation 19 9
Only MRT 44 15
MRT irradiation 20 minutes after injection of 56 μL of
DOTAREM® ([Gd]3+ = 1 M)
32 8
MRT irradiation 20 minutes after injection of 1.4 mL of
DOTAREM® ( [Gd]3+ = 40 mM])
43 8
MRT irradiation 20 minutes after injection of 1.4 mL
of AGuIX nanoparticles ( [Gd]3+ = 40 mM])
102.5 8
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also a strong residence time in the tumor; they remain for hours after the injection.
The plateau of MRI signal observed in the tumor, which can be linked to the gadolin-
ium concentration, is of importance for radiotherapy as irradiation can be performed
after the elimination of the nanoparticle from the blood circulation, while conserving
about the same quantity of nanoparticles in the tumor. The particles allow a
biodistribution that is very well suited for an optimal radiosensitization, thanks to
the EPR effect previously mentioned. The particle aspect of the AGuIX is now
proven to provide nanodose energy deposition in the vicinity of the nanoparticles.
This deposition is due to a series of absorption/emission of Auger electrons that
take place within the particles (also called Auger shower) between the Gd3+ cations
permitting the initiation of deleterious phenomena absent with commercial gadolinium
chelates. Therefore AGuIX nanoparticles present the characteristics of an adapted drug
for theranostic applications: contrast enhancement for MRI due to high relaxivity, high
radiosensitizing properties and adapted biodistribution (i.e. elimination by the kidneys
and passive accumulation in the tumor).
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